Eizen Joshua M — SEC insider filings
SEC reporting owner CIK 1949621. 14 insider filings on record with FilingPulse; latest filed 2026-11-06.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2022-10-28 to 2026-11-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 5 filings — 46,107 shares, $77,862 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 5,945 shares @ $4.17 ($24,803) in AN2 Therapeutics, Inc., filed 2026-07-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | See Remarks | 14 | — | 6 legs · 46,107 sh · $77,862 | 16 |
Insider filings — Eizen Joshua M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-06 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 2,826 @ $4.22 | EDGAR |
| 2026-07-10 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 5,945 @ $4.17 | EDGAR |
| 2026-03-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 92,000 (derivative) · Disposition to issuer (D): 92,000 (derivative) · Grant/award (A): 50,150 (derivative) · Disposition to issuer (D): 50,150 (derivative) | EDGAR |
| 2026-02-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 17,923 @ $1.00 · Sale (S): 6,931 @ $1.01 | EDGAR |
| 2025-11-06 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 2,819 @ $1.14 | EDGAR |
| 2025-02-28 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 58,500 @ $0 · Grant/award (A): 117,000 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 9,663 @ $1.34 | EDGAR |
| 2024-11-05 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 31,500 @ $0 · Grant/award (A): 63,000 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2024-03-29 | 4/A | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2024-03-18 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 50,150 (derivative) @ $0 | EDGAR |
| 2022-10-28 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 92,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-08 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1949621 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs